Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Collegium Falls in Aftermarket Trading After FDA Delays Ruling on Opioid Painkiller

CANTON, Mass. – Collegium Pharmaceutical, Inc. ’s (COLL) stock is down nearly 10 percent in aftermarket trading after the company announced the U.S. Food and Drug Administration will not complete a review of the company’s extended-release opioid pain medication drug Xtampza.   Michael Heffernan, Collegium’s chairman and chief executive officer, said the company remains confident […]

Read More »

Company Of The Year Gilead: Double The Dose

With not one but two record-shattering product launches that transformed the treatment of hepatitis C, Gilead more than doubled its revenue in a single year, earning its place as Med Ad News’ Company of the Year.

Read More »

Gilead Q&A: Paul Carter, Executive VP Of Commercial Operations

Med Ad News spoke with Paul Carter, Gilead’s executive VP of commercial operations, regarding the success of Sovaldi and Harvoni as well as the company’s vision of the future of biopharmaceuticals.

Read More »

Amgen: The Next Generation

Amgen has been an independent biotech leader for years with an established array of blockbuster products, and now the company’s next wave of promising medicines is making its mark.

Read More »

AstraZeneca: Pipeline And Partnerships

To accelerate the former, AstraZeneca has been engaging in a lot of the latter, as the company makes deals with other pharma and biotech companies as well as PatientsLikeMe.

Read More »

Exclusive – Transatlantic divide: How U.S. pays three times more for drugs

U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters.   The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such […]

Read More »

Bristol-Myers Squibb: Opdivo, And Everything Else

Between new approvals, new drug applications and research collaborations with other companies, most of the big news about Bristol-Myers Squibb in the past year has concerned the company’s newest immuno-oncologic drug.

Read More »

GlaxoSmithKline: Gaining Momentum

A three-part transaction with Novartis is anticipated to transform the future shape of GlaxoSmithKline, making the company more balanced and providing better opportunity for broadly based sales growth.

Read More »

Johnson & Johnson: Focused On Growth Drivers

J&J’s innovation strategy has created an industry-leading pipeline and a cycle of success that positions the company for continued growth.

Read More »

Lilly: Nowhere But Up

The leaders at Lilly knew that revenue would be bottoming out last year; with several recent new product approvals and more brewing in the pipeline, things are looking up in Indianapolis.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom